[Treatment of cutaneous T-cell lymphoma with retinoid receptor X-selective ligands: endocrine and metabolic disorders].
The retinoid X receptor-selective ligands has been used for advanced stages of cutaneous T-cell lymphoma refractory to previous systemic therapy, being bexarotene the first drug in this group approved in Europe. Multiple drug-related adverse events has been reported such as endocrine-metabolic disorders. We report 2 patients with cutaneous T-cell lymphoma, treated with bexarotene, that developed central hypothyroidism and dislipidaemia inmediately after the begining of this treatment. We also showed the successfully treatment response of these alterations and the total clinical remission after discontinuing the drug.
Avilés Pérez
M D
MD
Servicios de Endocrinología, Complejo Hospitalario Universitario, Badajoz, Spain.
Luna López
V
V
Rodríguez Nevado
I
I
de Argila Fernández-Durán
D
D
Díaz Pérez de Madrid
J
J
D016588:Anticarcinogenic Agents / Q000009:adverse effects*; D000077610:Bexarotene; D050171:Dyslipidemias / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007037:Hypothyroidism / Q000139:chemically induced*; D008024:Ligands; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D047488:Retinoid X Receptors; D012878:Skin Neoplasms / Q000188:drug therapy*; D013764:Tetrahydronaphthalenes / Q000009:adverse effects*
D016588:Anticarcinogenic Agents; D008024:Ligands; D047488:Retinoid X Receptors; D013764:Tetrahydronaphthalenes; D000077610:Bexarotene